Anju Peters, MD
Allergy & Immunology · Chicago, ILNPI 1952386054
Payments from drug & device makers
Across 856 payments — averaging $2499.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$696K
- Sanofi$441K
- Optinose US, Inc.$291K
- Regeneron$229K
- Merck$191K
- GSK$80K
- plus $212K from 15 others
Across 177 payments — averaging $612.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$44K
- Regeneron$38K
- Merck$22K
- Sanofi-aventis U.S. LLC$5K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 108 | $696,049 |
| Sanofi | 83 | $441,223 |
| Optinose US, Inc. | 39 | $290,596 |
| Regeneron | 450 | $228,948 |
| Merck | 14 | $191,124 |
| GSK | 54 | $80,001 |
| Eli Lilly | 31 | $69,422 |
| Regeneron Healthcare Solutions, Inc. | 29 | $39,105 |
| Astrazeneca UK Limited | 8 | $25,586 |
| Chiesi USA, Inc. | 3 | $15,820 |
| Insmed, Inc. | 2 | $15,000 |
| Sanofi US Services Inc. | 4 | $12,382 |
| Astrazeneca AB | 7 | $11,814 |
| Novartis | 11 | $10,621 |
| Sanofi-aventis U.S. LLC | 1 | $4,195 |
| Blueprint Medicines Corporation | 6 | $3,947 |
| Genentech, Inc. | 1 | $2,220 |
| Aerin Medical Inc. | 1 | $1,650 |
| Covis Pharma GmbH | 2 | $40 |
| Alk-abello, Inc | 1 | $17 |
| Bio Products Laboratory USA, Inc. | 1 | $8 |
How this compares
$2,139,768 in reported general payments places this provider in the 95th percentile of 161 allergy & immunology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other allergy & immunology in Chicago
- Giselle MosnaimChicago$2.2M
- Melanie MakhijaChicago$402K
- Elizabeth LippnerChicago$329K
- Christina CiaccioChicago$310K
- Amanda SalihChicago$160K
- Juanita MoraChicago$147K
- Gayatri PatelChicago$80K
- Sharmilee NyenhuisChicago$76K
- Michael FoggsChicago$71K
- Ayesha SiddiqiChicago$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.